Sana Biotechnology, Inc. (SANA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Sana Biotechnology reported revenue of $0. Net income was -$244.2M, or -$0.96 per diluted share. Operating activities generated -$143.8M of cash, leaving -$144.8M of free cash flow. At fiscal year end, Sana Biotechnology held $416.9M in total assets against $256.0M in total liabilities, including $71.9M of cash and equivalents.
Open the full interactive Sana Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
Sana Biotechnology Key Stats
| Share Price | $2.41 |
|---|---|
| Market Cap | $712.6M |
| 52-Week Range | $2.41 – $5.92 |
| Shares Outstanding | 295.7 million (basic, 2026 Q2) |
Sana Biotechnology Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$356.9M | -$272.6M | -$293.1M | -$272.7M | -$250.3M |
| Pre-Tax Income | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Diluted EPS | -$2.14 | -$1.43 | -$1.46 | -$1.16 | -$0.96 |
Sana Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$42.2M | -$58.8M | -$47.2M | -$63.6M |
| Diluted EPS | -$0.16 | -$0.23 | -$0.17 | -$0.22 |
Sana Biotechnology Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M |
| Current Assets | $558.1M | $444.4M | $213.5M | $160.8M | $148.7M |
| Total Assets | $1.13B | $822.7M | $565.3M | $501.0M | $416.9M |
| Current Liabilities | $99.2M | $111.5M | $64.5M | $45.4M | $78.7M |
| Total Liabilities | $400.9M | $323.4M | $277.8M | $250.5M | $256.0M |
| Shareholders' Equity | $728.5M | $499.3M | $287.5M | $250.5M | $160.9M |
Sana Biotechnology Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$251.1M | -$290.1M | -$253.6M | -$223.2M | -$143.8M |
| Cash From Investing | -$245.8M | $210.6M | $172.0M | $17.5M | -$40.2M |
| Cash From Financing | $631.8M | $4.9M | $31.6M | $199.7M | $128.7M |
| Free Cash Flow | -$280.9M | -$310.9M | -$273.6M | -$256.6M | -$144.8M |
Figures from Sana Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sana Biotechnology financials page for every line item.
Sana Biotechnology Company Profile
| Ticker | SANA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Seattle, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001770121 |
Frequently Asked Questions
What was Sana Biotechnology's revenue in fiscal 2025?
Sana Biotechnology (SANA) reported revenue of $0 for fiscal 2025.
What is Sana Biotechnology's annual revenue history?
Sana Biotechnology's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Sana Biotechnology's net income in fiscal 2025?
Sana Biotechnology reported net income of -$244.2M for fiscal 2025.
What was Sana Biotechnology's earnings per share (EPS) in fiscal 2025?
Sana Biotechnology's diluted EPS was -$0.96 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Sana Biotechnology generate in fiscal 2025?
Sana Biotechnology generated -$144.8M of free cash flow in fiscal 2025.
What was Sana Biotechnology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Sana Biotechnology reported revenue of $0.
How many shares of Sana Biotechnology are outstanding?
Sana Biotechnology reported a weighted average of 295.7 million basic shares outstanding in 2026 Q2.
What is Sana Biotechnology's market cap?
Based on its latest closing price, Sana Biotechnology (SANA) has a market capitalization of about $712.6M.
When does Sana Biotechnology's fiscal year end?
Sana Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is Sana Biotechnology headquartered?
Sana Biotechnology lists its business address in Seattle, Washington in its SEC filings.
Sana Biotechnology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →